Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Caicun Zhou, Di Ge et al.|The Lancet Respiratory Medicine|2021Cited by 183
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Yan Sun, Baohui Han et al.|Lung Cancer|2014Cited by 51
Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.Fenlai Tan, Yan Sun, Aiqin Gu et al.|Journal of Clinical Oncology|2013Cited by 5